Chronic Myeloid Leukemia Treatment Market Size & Growth Analysis to 2030

The global chronic myeloid leukemia (CML) treatment market has been projected to grow at the CAGR of ~ 3.5% market during 2017-2025 and expected to reach around USD 2 billion in terms of revenue by 2027. According to experts, chronic myelogenous leukemia (CML) arises once a pluripotent stem cell undergoes malignant transformation and clonal myeloproliferation, giving rise to a peaking overproduction of immature granulocytes. The National Cancer Institutes suggested that CML is a slowly progressing blood and bone marrow disease that usually occurs during or after middle age and rarely occurs in children. According to the World Health Organization (WHO), CML accounts for 15% of all leukemias in adults and approximately 8,220 new cases of CML will be diagnosed in 2016, with an estimated 1,070 deaths. The age-adjusted incidence is 1.6 per 100,000 populations.

Market Insights:

In chronic myeloid leukemia (CML) the bone marrow carries out uncontrolled production of white blood cells or granulocytes so much that it gradually crowd the bone marrow, interfering with normal blood cell production. In most of the chronic cases, these cells also spill out of the bone marrow and circulate around the body in the bloodstream. Due to the improper growth of white blood cells, they are unable to function properly to fight infections leading to a shortage of red blood cells and platelets leading to anemia, bleeding, and/or bruising. According to market experts, since the last decade exceptional progress has been carried out in the field of chronic myeloid leukemia (CML) treatment by providing multiple treatment options to patients.

In 2019, it was observed that BCR-ABL inhibitors accounted for the largest market share in CML treatment with first-generation imatinib and more effective second-generation BCR-ABL inhibitors such as nilotinib and dasatinib. However, the new members of the BCR-ABL inhibitors class such as ponatinib and bosutinib have been recently approved for market inclusion. A few research studies suggested that nilotinib and dasatinib possess high efficacy than imatinib in first-line chronic-phase CML (CML-CP) treatment, which is expected to give comparatively more rapid responses along with enhanced results in patients. The application of second- and third-generation therapies occurs in patients which are unable to gain sufficient benefits from Imatinib. The market stakeholders consider that the more potent second- and third-generation products have an opportunity to be used more widely due to a few properties possessed by these products to deliver a deeper and faster response, which could potentially prolong overall survival.

Market Segment Insights:

The global chronic myeloid leukemia (CML) market is segmented by treatment type. Based on treatment types, this market is categorized into targeted therapy, chemotherapy, radiation therapy, splenectomy, and stem cell transplant. The targeted therapy is further sub-segmented into imatinib, dasatinib, nilotinib, bosutinib, and ponatinib.  In 2019, targeted therapy accounted for the largest share of the CML treatment market due to high efficiency, increased life expectancy, insurance cover in developed and developing countries, and rising patient’s awareness related to the targeted therapy. A stem cell transplant may be an option for some younger patients, or patients who are intolerant or resistant to tyrosine kinase inhibitors (TKIs), providing them with a better chance of cure.

Global Chronic Myeloid Leukemia (CML) Market Segmentation:

By  Treatment Type, 2018–2027 ($ Millon)

• Targeted Therapy
  • Imatinib
  • Dasatinib
  • Nilotinib
  • Bosutinib
  • Ponatinib
• Chemotherapy
• Radiation Therapy
• Splenectomy
• Stem Cell Transplant

By Geography, 2018-2027 ($ Millon)

• North America
• Europe
• Asia Pacific
• Latin America (LATAM)
• Middle East and Africa (MEA)

Regional Insights:

In the year 2019, North America was observed as the leading geographical region in the chronic myeloid leukemia treatment market due to the rising diagnosis rate of chronic myeloid leukemia, market entry of novel targeted drug therapies, and an organized medical insurance environment. The American Cancer Society suggested that in the year 2016, about 8,220 new cases were diagnosed with CML (4,610 in men and 3,610 in women), and about 1,070 people died of CML (570 men and 500 women). Overall CML treatment market is growing slowly but upcoming drug approvals are expected to boost the market.

Market Competition Assessment:

Key players in the global chronic myeloid leukemia (CML) market are: Novartis AG, Bristol-Myers Squibb, Teva Pharmaceuticals Industries Ltd., ARIAD Pharmaceuticals, Inc., Prism Pharmaceuticals, Incyte Corporation, Bio-Path Holdings, Stragen Pharma SA, and others.

List of Key Companies:

• Novartis AG
• Bristol-Myers Squibb
• Teva Pharmaceuticals Industries Ltd.
• ARIAD Pharmaceuticals, Inc.
• Pfizer, Inc.
• Hospira, Inc.
• Prism Pharmaceuticals
• Incyte Corporation
• Bio-Path Holdings
• Stragen Pharma SA
• Otsuka Pharmaceutical Co., Ltd.

Request a full report sample in PDF format to review @ https://www.researchcorridor.com/request-sample/?id=144454